Search

Displaying results 2421 - 2430 of 7600 in total
  1. Drug

    Glimepiride

    go.drugbank.com/drugs/DB00222
    ApprovedInvestigational

    Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. … [A177703] Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in 1995 for the treatment of T2DM.

  2. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    Active and viable hematopoietic progenitor cells, or hematopoietic stem cells (HSCs) express the cell surface marker CD34 which is critical for cell identification [A32216]. … Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.

  3. Drug

    Golodirsen

    go.drugbank.com/drugs/DB15593
    ApprovedInvestigational

    [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of … [L10755,L10758] Golodirsen was initially rejected for FDA approval over concerns about its potential renal toxicity, however, clinical trials did not show significant toxicity.[L10755]

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Cefmenoxime

    go.drugbank.com/drugs/DB00267
    Approved

    Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of...

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil. … [A258318] The FDA approved the use of vardenafil for the treatment of erectile dysfunction in 2003.

  6. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    It is an attractive target for immunotherapy.

  7. Drug

    Roxithromycin

    go.drugbank.com/drugs/DB00778
    ApprovedInvestigationalWithdrawn

    It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections. … Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to [erythromycin], [azithromycin], or [clarithromycin].

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.

  9. Drug

    SUVN-502

    go.drugbank.com/drugs/DB06140
    Investigational

    SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer

  10. Drug

    Imipramine

    go.drugbank.com/drugs/DB00458
    ApprovedInvestigational

    TCAs also block histamine H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred … In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood.

    Categories: Antidepressive Agents Indicated for Depression